Royalty Report: Drugs, DNA, Medical – Collection: 294001

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • DNA
  • Medical
  • Drug Discovery
  • Biotechnology
  • Delivery
  • Disease
  • Genome
  • Therapeutic
  • Antibody
  • Agriculture
  • Forestry and Fishing
  • Technical Know How
  • Proteins
  • cell therapy
  • Diabetes Treatment
  • Nerve
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 294001

License Grant
Licensor of England agrees to grant to the Licensee a non-exclusive worldwide licence under the Patent Rights to develop manufacture use and sell Products.
License Property
This license is for the Zinc Fingers Patent.
A zinc finger is a small protein structural motif that is characterized by the coordination of one or more zinc ions in order to stabilize the fold.  Zinc finger proteins are among the most abundant proteins in eukaryotic genomes. Their functions are extraordinarily diverse and include DNA recognition, RNA packaging, transcriptional activation, regulation of apoptosis, protein folding and assembly, and lipid binding.

The Licensor has patent rights in respect of methods of selecting and designing polypeptides comprising zinc finger binding motifs and polypeptides made by those methods.

Field of Use
Licensee is in the research and development of novel transcription factors for the regulation of genes. Genes are composed of DNA and control the expression and transmission of all inherited traits.

IPSCIO Record ID: 367561

License Grant
Licensor agrees to grant to Licensee a royalty-bearing, worldwide, non-exclusive license under the Licensor Technology to use, distribute, reproduce, modify (without the use of ZFN Deliverables) and sell Modified Rats solely for the purpose of making, using and selling Licensee Products. Notwithstanding anything to the contrary in this Agreement, such license (a) does not include a license with respect to any genomic modifications that may be present in a Modified Rats that do not arise from or relate to a modification of the Target and (b) does not include any rights to any ZFPs. Licensor shall not (nor shall it authorize or assist any Third Party to) develop, use or transfer a ZFN Deliverable for the benefit of itself or any Third Party for use in connection with (whether directly or indirectly) inactivation of rat immunoglobulin expression in rat cells, tissues or whole animals for any purpose other than non-commercial research purposes provided, however, that Licensee’s sole remedy for any material breach of this covenant by Licensor or its Affiliates shall be termination of the Licensees payment obligations set forth.
License Property
Licensee Product means any product that is created or produced directly or indirectly by or on behalf of Licensee, its Affiliates, or its licensees or sublicensees through use or practice of Licensor Technology, including, without limitation, any Modified Rat or any antibodies created or produced through the use of a Modified Rat.

Licensor Patents means all Patents that (a) are Controlled by Licensor or its Affiliates as of the Effective Date or anytime during the term of this Agreement; and (b) claim or cover the Modified Rats or the use of the Modified Rats.

ZFPs means zinc-finger proteins (including a zinc-finger transcription factor or a zinc-finger nuclease), or a nucleic acid encoding and capable of expressing such protein in a cell or tissue.

Zinc finger proteins are among the most abundant proteins in eukaryotic genomes. Their functions are extraordinarily diverse and include DNA recognition, RNA packaging, transcriptional activation, regulation of apoptosis, protein folding and assembly, and lipid binding.

Field of Use
The license agreement is for the commercial use of a transgenic animal generated using o ZFP technology.

Field means use of Modified Rats to produce antibodies for clinical or commercial purposes.

IPSCIO Record ID: 26508

License Grant
The Licensor, a nonprofit medical research facility, desires to grant to Licensee an exclusive worldwide right and license to all remaining licensable fields useful with the technology and to certain patent rights and know-how of the Licensor with respect thereto, subject to the terms and conditions set forth herein.
License Property
The Licensor has been and is engaged in fundamental scientific biomedical and biochemical research including research relating to zinc finger proteins or ZFP's.

ZFPs are the most abundant class of transcription factors in humans and other higher organisms and naturally function to regulate gene expression.  By engineering ZFPs so that they can recognize a specific gene, we have created ZFP transcription factors that can control gene expression and, consequently, cell function.

IPSCIO Record ID: 6629

License Grant
Licensor hereby grants to Licensee, and Licensee hereby accepts from Licensor, upon the terms and conditions herein specified, a worldwide exclusive sublicense under the Patent Rights to make, to have made, to Use and to Sell Licensed Products in the Field.
License Property
Whereas, pursuant to Research and License Agreements dated May 1, 1982 and January 1, 1987. hereinafter collectively (the Scripps Agreements) between Licensor and Scripps Clinic and Research Foundation (hereinafter Scripps).

Scripps granted Licensor an exclusive option to obtain an exclusive worldwide license (including the right to grant sublicenses) to certain technology, including certain technology in the field of Zinc Finger Protein Derivatives (hereinafter the Inventions), and Licensor has exercised its option thereunder;  Whereas, patent applications have been filed in the United States and other territories in the name of Scripps for the granting of letters patent relating to the said Inventions, further described in Agreement hereto; and Whereas, Licensor desires that the Inventions be developed and made available to the public; and  Whereas, Licensee represents that it is presently engaged, or intends to be engaged in the business of research, development, manufacturing and selling products in fields related to the Inventions; and Whereas, Licensee wishes to make use of the Inventions for the research, development, manufacturing and selling of products and wishes to obtain certain rights to the Inventions under the terms and conditions hereinafter set forth; Whereas, Licensor is willing and able to grant such rights to Licensee.

A zinc finger is a small protein structural motif that is characterized by the coordination of one or more zinc ions in order to stabilize the fold.  Zinc finger proteins can be designed for highly specific recognition of any chosen DNA sequence.

Field of Use
Field shall mean the diagnoses, therapy or preventive treatment of diseases in humans or animals.

IPSCIO Record ID: 204831

License Grant
Licensor grants
– a worldwide, exclusive license to make, have made, use and sell Commodity Oilseed Products using Licensor’s Patent Rights, with rights to sublicense;
– a worldwide, non-exclusive royalty bearing license to make, have made, use and sell any Commodity Canela Products and subject to Licensor obtaining a third party permission, Commodity High Stearate Canola Products, so long as the products do not express herbicide resistance genes using Licensor’s Patent Rights, with rights to sublicense;
– a worldwide, co-exclusive with Licensor’s license to make, have made, use and sell Commodity Canola Products and subject to the third party written permission, Commodity High Stearate Canola Products, so long as the products express herbicide resistance genes, using Licensor’s Patent Rights,  and
– a worldwide, non-exclusive license, with no right to sublicense, to make, have made and use, for research purposes only, oilseed products other than Commodity Oilseed Products, Commodity Canola Products and Commodity High Stearate Canola Products using Licensor’s Patent Rights.
License Property
Licensor has certain technology useful in manipulating seed oil composition, and other technology applicable to the expression of traits in plants which can be used to express genes for oil modification,  meal modification or the  introduction of useful agronomic traits into oilseed crops.

Agronomic Genes shall mean genes encoding for disease resistance, herbicide tolerance, cold tolerance, shatter resistance, yield improvement,  earliness,  insect  tolerance,  drought  resistance  and heat resistance and other genes that reduce the net unit cost of production of agricultural crop plants.

The patents relate to Method & Compositions for Introducing Alien DNA in Vitro.

Field of Use
This agreement is for the agriculture production industry.

IPSCIO Record ID: 309676

License Grant
The Research Institute, a nonprofit American medical research facility, granted the Company in the Original Agreement a worldwide exclusive license to technology and patents for the research, development and commercialization of products and services using engineered ZFPs, excluding the use of these engineered ZFPs in plant agriculture, therapeutics and diagnostics.

The Licensee and Party A entered into a separate agreement which generated royalty payments to Licensee.

The Research Institute and the Company hereby agree to amend their original License Agreement with amendments based on the revenue from the agreement.

Royalty rate section updated with payments being paid on Primary Party A Revenue and Secondary Party A Revenue and no royalties due with respect of any Special Products.  Licensor acknowledges and agrees that the right to sublicense granted includes the right to sublicense to various sublicensees in different subfields of use within the Field (and in the case of nonexclusive sublicenses, overlapping subfields of use within the Field) but sublicensees cant not sublicense without prior written consent.

License Property
Zinc finger DNA-binding proteins (ZFPs), a naturally occurring class of proteins, that enable the modification of DNA sequences in a variety of ways.  The ZFP portion, the DNA-recognition domain, is typically composed of three or more zinc fingers. Each individual finger recognizes and binds to a three base pair sequence of DNA and multiple fingers can be linked together to recognize longer stretches of DNA, thereby improving specificity. By modifying the amino acids of a ZFP that directly interact with DNA, allows to engineer novel ZFPs capable of recognizing pre-selected DNA sequences within, or near, virtually any gene.

Party A Revenue means any cash compensation (including, without limitation, any fees, milestone payments, or running royalties (if any)) received by Licensee from Party A under the Party A Agreements.

The Primary and Secondary Revenue means the revenue covering the products containing a protein expressed by the modified cell line generated using the ZFN technology or any other technology that is covered by the ZFN-related intellectual property.

Field of Use
The field of use is used for the development of a ZFP TF activator of glial cell line-derived neurotrophic factor (GDNF) to treat Parkinson’s Disease (PD) and other diabetic neuropathy.

Licensee is a leader in the research, development and commercialization of zinc finger DNA-binding proteins (ZFPs), a naturally occurring class of proteins, and have used our knowledge and expertise to develop a proprietary technology platform. ZFPs can be engineered to make ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off, and ZFP nucleases (ZFNs), proteins that enable us to modify DNA sequences in a variety of ways. As ZFPs act at the DNA level, they have broad potential applications in several areas including cell-line engineering.

IPSCIO Record ID: 356265

License Grant
The Parties collaborate together to research, develop and commercialize therapeutic products in the Field and Licensee will have the exclusive option to take a license to each Product Candidate, whereby Licensor hereby grants to Licensee a worldwide, exclusive (even as to Licensor) license, with the right to sublicense, under Licensed IP, to Develop Elected Candidate and to Develop and Commercialize Licensed Product.
License Property
Licensor patents
US 5,464,758 – Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US 5,589,362 – Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US 5,654,168 – Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units

CAR T-cell therapy represents a promising, emerging approach to treating cancer. Blood is withdrawn from a patient and the T-cells are then extracted from a patient's blood. These cells are then genetically modified to recognize and attack cancer cells and then re-introduced into the patient's blood. The patient’s genetically modified cells are intended to bind to and kill the target cancer cells.

Field of Use
The  broad, global strategic collaboration is to discover, develop and commercialize novel diseasealtering gene therapies in oncology.

The collaboration will focus on applying gene therapy technology to genetically modify a patient’s own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.

Field means the use of (i) T-Cells expressing a CAR (with or without other engineering to enhance functionality and/or safety), including virus specific genetically modified T-Cells expressing a synthetic CAR, and (ii) T-Cells expressing native-virus antigen receptors or tumor-specific antigen receptors in which the T-Cells are genetically modified to enhance their performance, persistence or safety, in each case under (i) and (ii) for the treatment, modulation, palliation or prevention of cancer in humans.

IPSCIO Record ID: 128301

License Grant
For the Licensee products, Licensor grants a non-exclusive, non-transferable, worldwide license, without the right to grant sublicenses, under Licensor Technology and Licensor Patents to perform research and preclinical development in the Field during the research term using Licensee research genes.

Licensor grants a non-exclusive, non-transferable options to obtain licenses for up to three (3) Licensee research genes exercisable during the research term of this Agreement.

Licensor grants an exclusive worldwide license, with the right to grant sublicenses, under Licensor Technology and Patents to research, develop, make, have made, use, import, export, offer to sell and sell such exclusive Licensee products in the field.

License Property
The Licensors patents include the Delivery of Exogenous DNA Sequences in a Mammal and the Production of Pharmaceutical-Grade Plasmid DNA.
Field of Use
The field is the intervention, treatment and/or prevention of a disease or disorder in humans by Gene therapy.

IPSCIO Record ID: 203979

License Grant
Licensor grants a nonexclusive, non-transferable, worldwide license, without the right to grant sublicenses, under Licensors technology and patents to perform research and preclinical development in the field during the research term using Licensee research genes.

Licensor grants non-exclusive, non-transferable options to obtain licenses for up to three (3) Licensee identified Research Genes exercisable during the research term of this Agreement.

With respect to exclusive Licensee products directed to a Licensee research gene for which Licensee has exercised an option Licensor is obligated to grant a license.  Licensor grants to Licensee an exclusive worldwide license under Licensor technology and patents to research, develop, make, have made, use, import, export, offer to sell and sell such exclusive Licensee products in the field.

License Property
The Licensed patents include the Delivery of Exogenous DNA Sequences in a Mammal and the Production of Pharmaceutical-Grade Plasmid DNA.
Field of Use
The field is the intervention, treatment and/or prevention of a disease or disorder in humans by Gene therapy.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.